Retrospective data study evaluating resource utilization among metastatic renal cell carcinoma patients receiving oral versus intravenous mTOR inhibitors.

Abstract

e15063 Background: The purpose of this retrospective study was to compare healthcare resource utilization among metastatic renal cell carcinoma (mRCC) patients (pts) receiving everolimus (oral mTOR inhibitor), relative to pts receiving temsirolimus (intravenous mTOR inhibitor). Methods: Using US Oncology’s iKnowMed EMR in conjunction with claims and pharmacy data, we identified mRCC pts who initiated a treatment regimen of everolimus or temsirolimus from 2009 –2010 with a minimal six month follow-up period. Healthcare encounters were estimated and presented using the per patient per month metric. Poisson regression models were used to examine the impact of treatment on resource use after controlling for covariates including stage, ECOG status, and insurance type, and were stratified by line of therapy (LOT) as LOT was the most significant different baseline characteristic between the two treatment groups. Results: A total of 461 pts were identified: 143 were treated with everolimus, and 318 with temsirolimus. The everolimus group had lower usage of all types of services than the temsirolimus group and the results were statistically significant for most of the categories as per the bivariate analysis. In the multivariate analysis stratified by LOT and adjusted for baseline characteristics, the temsirolimus group had statistically significant more acute care services (1st line), drug usages (1st and 2nd line), lab visits (2nd and 3rd line), radiation treatment and minor services (2nd line), non-drug and other services (1st, 2nd, and 3rd line), than the everolimus group. Conclusions: Results of this retrospective study suggest that overall everolimus is associated with lower patient burden in terms of health care resource utilization relative to temsirolimus.